Intercept Pharma

Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Fierce Biotech
Ipsen
Genfit
elafibranor
liver disease
Intercept Pharma
CymaBay Therapeutics
Flag link:
Alfasigma To Acquire Intercept Pharma For $19 Per Share In Cash
Alfasigma To Acquire Intercept Pharma For $19 Per Share In Cash
RTT News
Intercept Pharma
M&A
Alfasigma
NASH
Flag link:
Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space
Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space
BioSpace
Intercept Pharma
NASH
obeticholic acid
Flag link:
Intercept restructures as Ocaliva's NASH hopes dashed again with FDA rejection
Intercept restructures as Ocaliva's NASH hopes dashed again with FDA rejection
Fierce Pharma
Intercept Pharma
NASH
Ocaliva
obeticholic acid
FDA
Flag link:
Future of Intercept’s NASH drug in doubt after FDA panel rejection
Future of Intercept’s NASH drug in doubt after FDA panel rejection
BioPharma Dive
Intercept Pharma
FDA
NASH
obeticholic acid
Flag link:
FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks
FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks
BioPharma Dive
FDA
NASH
OCA
obeticholic acid
Intercept Pharma
Flag link:
FDA schedules adcomms for Entasis' antimicrobial treatment, Intercept's NASH hopeful
FDA schedules adcomms for Entasis' antimicrobial treatment, Intercept's NASH hopeful
Endpoints
FDA
Entasis
Intercept Pharma
sulbactam-durlobactam
obeticholic acid
NASH
Flag link:
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
Clinical Trials Arena
FDA
Intercept Pharma
OCA
obeticholic acid
NASH
Flag link:
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
BioSpace
NASH
Intercept Pharma
Novo Nordisk
Madrigal Pharmaceuticals
Inventiva
Galmed Pharmaceuticals
Flag link:
Ocaliva fails NASH trial just as Intercept charts path toward FDA application
Ocaliva fails NASH trial just as Intercept charts path toward FDA application
Fierce Pharma
Intercept Pharma
NASH
obeticholic acid
Ocaliva
clinical trials
FDA
Flag link:
Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug
Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug
Endpoints
Intercept Pharma
OCA
obeticholic acid
FDA
NASH
Flag link:
Key data catalysts for the industry’s small players
Key data catalysts for the industry’s small players
EP Vantage
Intercept Pharma
Akero
NASH
Kymera
atopic dermatitis
Zealand Pharma
short bowel syndrome
Relmada
Verona
Anavex
Assembly Biosciences
Aldeyra
Flag link:
Intercept sells international rights to liver drug in $400M deal
Intercept sells international rights to liver drug in $400M deal
BioPharma Dive
Intercept Pharma
Advanz Pharma
Ocaliva
liver disease
Flag link:
3 Biotech Stocks With Major Catalysts in January
3 Biotech Stocks With Major Catalysts in January
Motley Fool
Novavax
vaccines
COVID-19
FDA
Intercept Pharma
Ocaliva
NASH
Madrigal Pharmaceuticals
resmetirom
Flag link:
10 clinical trials to watch in the first half of 2022
10 clinical trials to watch in the first half of 2022
BioPharma Dive
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Sanofi
GSK
vaccines
COVID-19
Roche
gantenerumab
AbbVie
Gilead Sciences
Trodelvy
Karuna Therapeutics
KarXT
Intercept Pharma
obeticholic acid
Allogene
ALLO-501a
Flag link:
Intercept, awaiting needed trial data, pulls its NASH drug application in Europe
Intercept, awaiting needed trial data, pulls its NASH drug application in Europe
BioPharma Dive
Intercept Pharma
NASH
Europe
obeticholic acid
Flag link:
FDA adds new 'do not use' note to Intercept's Ocaliva label after a slew of side effect reports in cirrhosis patients
FDA adds new 'do not use' note to Intercept's Ocaliva label after a slew of side effect reports in cirrhosis patients
Endpoints
Intercept Pharma
NASH
Ocaliva
FDA
primary biliary cholangitis
Flag link:
Intercept shakeup continues as CMO, former NASH chief resigns. Is the NASH biotech abandoning its flagship disease?
Intercept shakeup continues as CMO, former NASH chief resigns. Is the NASH biotech abandoning its flagship disease?
Endpoints
Intercept Pharma
NASH
Flag link:
Longtime Intercept CEO Mark Pruzanski departs as ailing NASH company tries to find its future
Longtime Intercept CEO Mark Pruzanski departs as ailing NASH company tries to find its future
Endpoints
Mark Pruzanski
Pharma CEOs
Intercept Pharma
NASH
Flag link:
Shedding light on Intercept’s opaque disclosure
Shedding light on Intercept’s opaque disclosure
EP Vantage
Intercept Pharma
Ocaliva
NASH
drug safety
Flag link:

Pages